<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02760433</url>
  </required_header>
  <id_info>
    <org_study_id>CL04041025</org_study_id>
    <secondary_id>2015-005308-27</secondary_id>
    <nct_id>NCT02760433</nct_id>
  </id_info>
  <brief_title>Evaluation of the Efficacy and Safety of Two Dosing Regimens of Olokizumab (OKZ), Compared to Placebo, in Subjects With Rheumatoid Arthritis (RA) Who Were Taking an Existing Medication Called a Tumour Necrosis Factor Alpha Inhibitor But Had Active Disease</brief_title>
  <acronym>CREDO 3</acronym>
  <official_title>A Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Phase III Study of the Efficacy and Safety of Olokizumab in Subjects With Moderately to Severely Active Rheumatoid Arthritis Inadequately Controlled by Tumor Necrosis Factor Alpha (TNF-α) Inhibitor Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>R-Pharm International, LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Quintiles, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>OCT Clinical Trials</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Mene Research</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>R-Pharm</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study was to determine how effective and safe the study drug Olokizumab&#xD;
      is, in patients with Rheumatoid Arthritis (RA) who were already receiving, but not fully&#xD;
      responding to treatment with an existing medication called a tumour necrosis factor alpha&#xD;
      inhibitor&#xD;
&#xD;
      The primary objective of this study was to evaluate the efficacy of olokizumab (OKZ) 64 mg&#xD;
      administered subcutaneously (SC) once every 2 weeks (q2w) or once every 4 weeks (q4w)&#xD;
      relative to placebo in subjects with moderately to severely active rheumatoid arthritis (RA)&#xD;
      inadequately controlled by TNF-α inhibitor (TNFi) therapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The goal of this Phase III study was to assess the efficacy, safety and tolerability of OKZ&#xD;
      in subjects with moderately to severely active RA who had responded inadequately to TNFi&#xD;
      therapy. The primary endpoint of the trial was assessed at Week 12. Olokizumab was expected&#xD;
      to reduce the disease activity and improve physical function. The study was expected to&#xD;
      provide safety information in a large group of subjects over at least a 24 week period.&#xD;
&#xD;
      This was a randomized, double-blind, parallel-group, placebo-controlled, multicenter study.&#xD;
      This study included a 4-week Screening Period, a double-blind Treatment Period from Week 0 to&#xD;
      Week 24, and a Safety FollowUp Period from Week 24 to Week 44.&#xD;
&#xD;
      A total of 350 subjects were planned to be randomized.Subjects were assessed for eligibility&#xD;
      to enter the study during a 4-week Screening Period. Eligible subjects were randomized at&#xD;
      Visit 2 in a 2:2:1 ratio in one of 3 treatment groups (planned 140, 140, and 70 subjects per&#xD;
      group, respectively) :&#xD;
&#xD;
        1. Olokizumab 64 mg q4w: SC injection of OKZ 64 mg q4w (alternating with SC injection of&#xD;
           placebo OKZ q4w to maintain blinding) + MTX for 24 weeks,&#xD;
&#xD;
        2. Olokizumab 64 mg q2w: SC injection of OKZ 64 mg q2w + MTX for 24 weeks or&#xD;
&#xD;
        3. Placebo: SC injection of placebo q2w + MTX for 16 weeks.&#xD;
&#xD;
      Subjects who received placebo were re-randomized at Week 16 to receive 64 mg OKZ q4w +&#xD;
      Methotrexate or 64 mg OKZ q2w +Methotrexate for 8 weeks.&#xD;
&#xD;
      Throughout the double-blind Treatment Period, all subjects were required to remain on a&#xD;
      stable dose of background MTX with a stable route of administration. Concomitant treatment&#xD;
      with folic acid was required for all subjects. The last dose of study treatment (OKZ) was at&#xD;
      Week 22 in all groups.&#xD;
&#xD;
      Following Visit 2 (randomization; Week 0), subjects returned to the study site at least every&#xD;
      2 weeks through Week 24 for response and safety assessments.&#xD;
&#xD;
      At Week 14, subjects who did not improve by at least 20% in both swollen and tender joint&#xD;
      counts were classified as nonresponders and were administered sulfasalazine and/or&#xD;
      hydroxychloroquine as rescue medication in addition to the assigned treatment.&#xD;
&#xD;
      After completion of the 24-week double-blind Treatment Period, subjects either rolled over&#xD;
      into the long-term open-label extension (OLE) study or entered the Safety Follow-Up Period.&#xD;
      During the Safety Follow-Up Period, subjects returned for visits +4, +8, and +22 weeks after&#xD;
      the last dose of study treatment.&#xD;
&#xD;
      Subjects who discontinued randomized treatment prematurely were required to come for the End&#xD;
      of Treatment (EoT) Visit 2 weeks after the last study treatment administration and then&#xD;
      continue with the scheduled study visits.&#xD;
&#xD;
      Adverse events (AEs) were assessed throughout the study (starting when the subject signed the&#xD;
      informed consent form) and evaluated using the Common Terminology Criteria for Adverse Events&#xD;
      Version 4.0. There was ongoing monitoring of safety events, including laboratory findings, by&#xD;
      the Sponsor or the Sponsor's designee. In addition, safety was assessed throughout the study&#xD;
      by an independent Data Safety Monitoring Board and potential major adverse cardiac events&#xD;
      were evaluated by an independent Cardiovascular Adjudication Committee.&#xD;
&#xD;
      The study was conducted at 123 sites across 11 countries globally (in US,EU, Russian&#xD;
      Federation, Asia, Latin America)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 9, 2017</start_date>
  <completion_date type="Actual">October 1, 2019</completion_date>
  <primary_completion_date type="Actual">September 12, 2019</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>ACR20 Response</measure>
    <time_frame>at Week 12</time_frame>
    <description>The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.&#xD;
American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Difference Between OKZ and Placebo in the Percentage of Subjects Achieving Low Disease Activity</measure>
    <time_frame>at Week 12</time_frame>
    <description>Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference Between OKZ and Placebo in the Improvement of Physical Ability</measure>
    <time_frame>Baseline to Week 12</time_frame>
    <description>Improvement of physical ability from baseline to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 to 3, with higher scores indicating greater disability.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ACR50 Response</measure>
    <time_frame>at Week 12</time_frame>
    <description>Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 12.&#xD;
American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical Disease Activity Index (CDAI) ≤2.8 (Remission)</measure>
    <time_frame>at Week 12</time_frame>
    <description>Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 12</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">368</enrollment>
  <condition>Rheumatoid Arthritis</condition>
  <arm_group>
    <arm_group_label>Arm 1: Olokizumab q4w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate&#xD;
Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 2: Olokizumab q2w</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm 3: Placebo q2w</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo q2w subcutaneous + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)&#xD;
Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w; equal numbers of subjects were planned to be assigned to each OKZ treatment group.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olokizumab</intervention_name>
    <description>160 mg/mL sterile solution for SC injection in a 2 mL clear Type I glass vial, containing a target fill volume of 1.1 mL (for withdrawal of not less than 0.8 mL) or a target fill volume of 0.5 mL (for withdrawal of not less than 0.4 mL)</description>
    <arm_group_label>Arm 1: Olokizumab q4w</arm_group_label>
    <arm_group_label>Arm 2: Olokizumab q2w</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>sodium chloride 0.9% solution provided as either a 10 mL vial or ampoule, depending on market availability. Each placebo will be packed into a cardboard carton to contain 1 vial or ampoule</description>
    <arm_group_label>Arm 1: Olokizumab q4w</arm_group_label>
    <arm_group_label>Arm 3: Placebo q2w</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects may be enrolled in the study only if they meet all of the following criteria.&#xD;
&#xD;
          -  Subjects willing and able to sign informed consent&#xD;
&#xD;
          -  Subjects must have a diagnosis of adult onset RA classified by ACR/EULAR 2010 revised&#xD;
             classification criteria for RA for at least 24 weeks prior to Screening.&#xD;
&#xD;
        (If the subject was diagnosed according to ACR 1987 criteria previously, the Investigator&#xD;
        may classify the subject per ACR 2010 retrospectively, using available source data.)&#xD;
&#xD;
          -  Treatment with oral, SC, or intramuscular (IM) MTX for at least 12 weeks prior to&#xD;
             Screening at a dose of 15 to 25 mg/week (or ≥10 mg/week if there is documented&#xD;
             intolerance to higher doses)&#xD;
&#xD;
               -  The dose and means of administering MTX must have been stable for at least 6&#xD;
                  weeks prior to Screening.&#xD;
&#xD;
          -  Subjects must be willing to take folic acid or equivalent throughout the study.&#xD;
&#xD;
          -  Subjects must have moderately to severely active RA disease as defined by all of the&#xD;
             following:&#xD;
&#xD;
               -  ≥6 tender joints (68 joint count) at Screening and baseline; and&#xD;
&#xD;
               -  ≥6 swollen joints (66 joint count) at Screening and baseline; and&#xD;
&#xD;
               -  CRP above ULN at Screening based on the central laboratory results.&#xD;
&#xD;
          -  Subjects must have a documented inadequate response to treatment (i.e., TNFi failure)&#xD;
             with ≥1 licensed TNFi following at least 12 weeks of therapy with that agent.&#xD;
             Inadequate response to treatment is classified as either:&#xD;
&#xD;
               -  Primary failure: The absence of any documented clinically significant response;&#xD;
                  or&#xD;
&#xD;
               -  Secondary failure: Documented initial response with subsequent loss of that&#xD;
                  response or partial response&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Diagnosis of any other inflammatory arthritis or systemic rheumatic disease (e.g.,&#xD;
             gout, psoriatic or reactive arthritis, Crohn's disease, Lyme disease, juvenile&#xD;
             idiopathic arthritis, or systemic lupus erythematosus) (However, subjects may have&#xD;
             secondary Sjogren's syndrome or hypothyroidism.)&#xD;
&#xD;
          -  Subjects who are Steinbrocker class IV functional capacity (incapacitated, largely or&#xD;
             wholly bed-ridden or confined to a wheelchair, with little or no self-care)&#xD;
&#xD;
          -  Prior exposure to any licensed or investigational compound directly or indirectly&#xD;
             targeting IL 6 or IL 6R (including tofacitinib or other Janus kinases and spleen&#xD;
             tyrosine kinase [SYK] inhibitors)&#xD;
&#xD;
          -  Prior treatment with cell depleting therapies including anti CD20 or investigational&#xD;
             agents (e.g., CAMPATH, anti CD4, anti CD5, anti CD3, and anti CD19) with the exception&#xD;
             of rituximab, which is allowed if it was discontinued at least 24 weeks prior to&#xD;
             baseline (rituximab should not be discontinued to facilitate a subject's participation&#xD;
             in the study, but should instead have been previously discontinued as part of a&#xD;
             subject's medical management of RA).&#xD;
&#xD;
          -  Prior use of bDMARDs, within the following windows prior to baseline (bDMARDs should&#xD;
             not be discontinued to facilitate a subject's participation in the study, but should&#xD;
             instead have been previously discontinued as part of a subject's medical management of&#xD;
             RA):&#xD;
&#xD;
               1. 4 weeks for etanercept and anakinra&#xD;
&#xD;
               2. 8 weeks for infliximab&#xD;
&#xD;
               3. 10 weeks for adalimumab, certolizumab, and golimumab&#xD;
&#xD;
               4. 12 weeks for abatacept&#xD;
&#xD;
          -  Use of parenteral and/or intra-articular glucocorticoids within 4 weeks prior to&#xD;
             baseline&#xD;
&#xD;
          -  Use of oral glucocorticoids greater than 10 mg/day prednisone (or equivalent) or&#xD;
             change in dosage within 2 weeks prior to baseline&#xD;
&#xD;
          -  Prior documented history of no response to hydroxychloroquine and sulfasalazine&#xD;
&#xD;
          -  Prior use of cDMARDs (other than MTX) within the following windows prior to baseline&#xD;
             (cDMARDs should not be discontinued to facilitate a subject's participation in the&#xD;
             study, but should instead have been previously discontinued as part of a subject's&#xD;
             medical management of RA):&#xD;
&#xD;
               1. 4 weeks for sulfasalazine, azathioprine, cyclosporine, hydroxychloroquine,&#xD;
                  chloroquine, gold, penicillamine, minocycline, or doxycycline&#xD;
&#xD;
               2. 12 weeks for leflunomide unless the subject has completed the following&#xD;
                  elimination procedure at least 4 weeks prior to baseline: Cholestyramine at a&#xD;
                  dosage of 8 grams 3 times daily for at least 24 hours, or activated charcoal at a&#xD;
                  dosage of 50 grams 4 times daily for at least 24 hours&#xD;
&#xD;
               3. 24 weeks for cyclophosphamide&#xD;
&#xD;
          -  Vaccination with live vaccines in the 6 weeks prior to baseline or planned vaccination&#xD;
             with live vaccines during the study&#xD;
&#xD;
          -  Participation in any other investigational drug study within 30 days or 5 times the&#xD;
             terminal half-life of the investigational drug, whichever is longer, prior to baseline&#xD;
&#xD;
          -  Other treatments for RA (e.g., Prosorba Device/Column) within 6 months prior to&#xD;
             baseline&#xD;
&#xD;
          -  Use of intra-articular hyaluronic acid injections within 4 weeks prior to baseline&#xD;
&#xD;
          -  Use of non steroidal anti inflammatory drugs (NSAIDs) on unstable dose or switching of&#xD;
             NSAIDs within 2 weeks prior to baseline&#xD;
&#xD;
          -  Previous participation in this study (randomized) or another study of OKZ&#xD;
&#xD;
          -  Abnormal laboratory values as defined below:&#xD;
&#xD;
               -  Creatinine level ≥ 1.5 mg/dL (132 µmol/L) for females or ≥ 2.0 mg/dL (177 µmol/L)&#xD;
                  for males&#xD;
&#xD;
               -  ALT or AST level ≥ 1.5 x ULN&#xD;
&#xD;
               -  Platelets &lt; 100 x 10^9/L (&lt;100,000/mm^3)&#xD;
&#xD;
               -  White blood cell count &lt; 3.5 x 10^9/L&#xD;
&#xD;
               -  Neutrophil count &lt;2000 x 10^6/L (&lt;2000/mm^3)&#xD;
&#xD;
               -  Hemoglobin level ≤ 80 g/L&#xD;
&#xD;
               -  Glycosylated hemoglobin (HbA1c) level ≥ 8%&#xD;
&#xD;
          -  Subjects with concurrent acute or chronic viral Hepatitis B or C infection as detected&#xD;
             by blood tests at Screening (e.g., positive for hepatitis B surface antigen [HBsAg],&#xD;
             total hepatitis B core antibody [anti-HBc], or hepatitis C virus antibody [HCV Ab])&#xD;
&#xD;
             a) subjects who are positive for hepatitis B surface antibodies (anti-HBs), but&#xD;
             negative for HBsAg and anti-HBc, will be eligible.&#xD;
&#xD;
          -  Subjects with HIV infection&#xD;
&#xD;
          -  Subjects with:&#xD;
&#xD;
               1. Suspected or confirmed current active TB disease or a history of active TB&#xD;
                  disease.&#xD;
&#xD;
               2. Close contact (i.e., sharing the same household or other enclosed environment,&#xD;
                  such as a social gathering place, workplace, or facility, for extended periods&#xD;
                  during the day) with an individual with active TB within 1.5 years prior to&#xD;
                  Screening&#xD;
&#xD;
               3. History of untreated latent TB infection (LTBI), regardless of IGRA result at&#xD;
                  Screening&#xD;
&#xD;
             i. Subjects with a history of untreated LTBI may be re-screened and enrolled if they&#xD;
             fulfill all 3 of the following criteria:&#xD;
&#xD;
             1. Active TB is ruled out by a certified TB specialist or pulmonologist who is&#xD;
             familiar with diagnosing and treating TB (as acceptable per local practice); 2. The&#xD;
             subject has completed at least 30 days of LTBI-appropriate prophylaxis prior to&#xD;
             baseline with agents recommended as preventative therapy for LTBI according to&#xD;
             country-specific/Centers for Disease Control and Prevention (CDC) guidelines&#xD;
             (treatment with isoniazid for 6 months is not an appropriate prophylactic regime for&#xD;
             this study and it should not be used); and 3. The subject is willing to complete the&#xD;
             entire course of recommended LTBI therapy d. Positive interferon-gamma release assay&#xD;
             (IGRA) result at Screening. If indeterminate, the IGRA can be repeated once during the&#xD;
             Screening Period. If there is a second indeterminate result, the subject will be&#xD;
             excluded.&#xD;
&#xD;
             i. Subjects with a positive IGRA result at Screening may be re-screened and enrolled&#xD;
             if they fulfill all 3 of the following criteria:&#xD;
&#xD;
               1. Active TB is ruled out by a certified TB specialist or pulmonologist who is&#xD;
                  familiar with diagnosing and treating TB (as acceptable per local practice);&#xD;
&#xD;
               2. The subject has completed at least 30 days of LTBI-appropriate prophylaxis prior&#xD;
                  to baseline with agents recommended as preventative therapy for LTBI according to&#xD;
                  country-specific/CDC guidelines and&#xD;
&#xD;
               3. The subject is willing to complete the entire course of recommended LTBI therapy&#xD;
                  ii. If a subject with a positive IGRA result at Screening has documented evidence&#xD;
                  of completing treatment for LTBI with a treatment regime and treatment duration&#xD;
                  that are appropriate for this study, the subject may be enrolled without further&#xD;
                  prophylaxis if recommended by a certified TB specialist or pulmonologist who is&#xD;
                  familiar with diagnosing and treating TB (as acceptable per local practice) and&#xD;
                  no new exposure in close contact with an individual with active TB after&#xD;
                  completing the prophylactic treatment is suspected&#xD;
&#xD;
          -  Concurrent malignancy or a history of malignancy within the last 5 years (with the&#xD;
             exception of successfully treated carcinoma of the cervix in situ and successfully&#xD;
             treated basal cell carcinoma and squamous cell carcinoma not less than 1 year prior to&#xD;
             Screening [and no more than 3 excised skin cancers within the last 5 years prior to&#xD;
             Screening])&#xD;
&#xD;
          -  Subjects with any of the following CV conditions:&#xD;
&#xD;
               1. Uncompensated congestive heart failure, or class III or IV heart failure defined&#xD;
                  by the New York Heart Association classification (The Criteria Committee of the&#xD;
                  New York Heart Association, 1994)&#xD;
&#xD;
               2. Untreated or resistant arterial hypertension Grade II-III (systolic blood&#xD;
                  pressure [BP] &gt;160 mm Hg and/or diastolic BP &gt;100 mm Hg)&#xD;
&#xD;
               3. History or presence of concurrent severe and/or uncontrolled CV disorder&#xD;
                  (including but not limited to acute coronary syndrome or stroke/transient&#xD;
                  ischemic attack in the previous 3 months before Screening) that would, in the&#xD;
                  Investigator's judgment, contraindicate subject participation in the clinical&#xD;
                  study, or clinically significant enough in the opinion of the Investigator to&#xD;
                  alter the disposition of the study treatment, or constitute a possible&#xD;
                  confounding factor for assessment of efficacy or safety of the study treatment&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Subjects with any infection requiring oral antibiotic or antiviral therapy in the 2&#xD;
             weeks prior to Screening or at baseline, injectable anti-infective therapy in the last&#xD;
             4 weeks prior to baseline, or serious or recurrent infection with history of&#xD;
             hospitalization in the 6 months prior to baseline&#xD;
&#xD;
          -  Subjects with evidence of disseminated herpes zoster infection, zoster encephalitis,&#xD;
             meningitis, or other non-self-limited herpes zoster infections in the 6 months prior&#xD;
             to baseline&#xD;
&#xD;
          -  Subjects with planned surgery during the study or surgery ≤ 4 weeks prior to Screening&#xD;
             and from which the subject has not fully recovered, as judged by the Investigator&#xD;
&#xD;
          -  Subjects with diverticulitis or other symptomatic GI conditions that might predispose&#xD;
             the subject to perforations, including subjects with history of such predisposing&#xD;
             conditions (e.g., diverticulitis, GI perforation, or ulcerative colitis)&#xD;
&#xD;
          -  Pre-existing central nervous system demyelinating disorders (e.g., multiple sclerosis&#xD;
             and optic neuritis)&#xD;
&#xD;
          -  History of chronic alcohol or drug abuse as judged by the Investigator&#xD;
&#xD;
          -  Female subjects who are pregnant, currently lactating, have lactated within the last&#xD;
             12 weeks, or who are planning to become pregnant during the study or within 6 months&#xD;
             of the last dose of study treatment&#xD;
&#xD;
          -  Female subjects of childbearing potential (unless permanent cessation of menstrual&#xD;
             periods, determined retrospectively after a woman has experienced 12 months of natural&#xD;
             amenorrhea as defined by the amenorrhea with underlying status [e.g., correlative age]&#xD;
             or 6 months of natural amenorrhea with documented serum follicle-stimulating hormone&#xD;
             levels &gt;40 mIU/mL and estradiol &lt;20 pg/mL) who are not willing to use a highly&#xD;
             effective method of contraception during the study and for at least 6 months after the&#xD;
             last administration of study treatment&#xD;
&#xD;
        OR&#xD;
&#xD;
        Male subjects with partners of childbearing potential not willing to use a highly effective&#xD;
        method of contraception during the study and for at least 3 months after the last&#xD;
        administration of study treatment.&#xD;
&#xD;
        Highly effective contraception is defined as:&#xD;
&#xD;
          -  Female sterilization surgery: hysterectomy, surgical bilateral oophorectomy (with or&#xD;
             without hysterectomy) or tubal ligation at least 6 weeks prior to the first dose of&#xD;
             study treatment&#xD;
&#xD;
             - In the case of oophorectomy alone, only when the reproductive status of the woman&#xD;
             has been confirmed by documented follow-up hormone level assessment&#xD;
&#xD;
          -  Total abstinence if it is the preferred and constant lifestyle of the subject. Thus,&#xD;
             periodic abstinence such as ovulation, symptothermal, postovulation, calendar methods,&#xD;
             and withdrawal are not acceptable methods of contraception.&#xD;
&#xD;
          -  Male sterilization surgery: at least 6 months prior to Screening (with the appropriate&#xD;
             postvasectomy documentation of the absence of sperm in the ejaculate). For female&#xD;
             subjects, the vasectomized male should be the only partner.&#xD;
&#xD;
          -  Placement of established intrauterine device (IUD): IUD copper or IUD with&#xD;
             progesterone&#xD;
&#xD;
          -  Barrier method (condom and intravaginal spermicide, cervical caps with spermicide,&#xD;
             diaphragma with spermicide) in combination with the following: established oral,&#xD;
             injected, or implanted hormone methods of contraception or contraceptive patch&#xD;
&#xD;
               -  Subjects with a known hypersensitivity to any component of the OKZ drug product&#xD;
                  or placebo&#xD;
&#xD;
               -  Subjects with a known hypersensitivity or contraindication to any component of&#xD;
                  the rescue medication&#xD;
&#xD;
               -  History of severe allergic or anaphylactic reactions to human, humanized, or&#xD;
                  murine monoclonal antibodies&#xD;
&#xD;
               -  Subject's unwillingness or inability to follow the procedures outlined in the&#xD;
                  protocol&#xD;
&#xD;
               -  Other medical or psychiatric conditions or laboratory abnormalities that may&#xD;
                  increase potential risk associated with study participation and administration of&#xD;
                  investigational products, or that may affect study results interpretation and, as&#xD;
                  per the Investigator's judgment, make the subject ineligible&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mikhail Samsonov</last_name>
    <role>Study Director</role>
    <affiliation>R-Pharm</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Arizona Arthritis &amp; Rheumatology Associates, P.C.</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85304</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Arthritis &amp; Rheum Research</name>
      <address>
        <city>Mesa</city>
        <state>Arizona</state>
        <zip>85210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHI St. Vincent Hot Springs</name>
      <address>
        <city>Hot Springs</city>
        <state>Arkansas</state>
        <zip>71913</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medvin Clinical Research</name>
      <address>
        <city>Covina</city>
        <state>California</state>
        <zip>91722</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TriWest Research Associates, LLC</name>
      <address>
        <city>El Cajon</city>
        <state>California</state>
        <zip>92020-4124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Jude Heritage Medical Grp</name>
      <address>
        <city>Fullerton</city>
        <state>California</state>
        <zip>92835</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>С V Mehta MD Med Corp.</name>
      <address>
        <city>Hemet</city>
        <state>California</state>
        <zip>92543</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Medical Research, LLC</name>
      <address>
        <city>Lakewood</city>
        <state>California</state>
        <zip>90623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Riverside Medical Clinic</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>92506</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>East Bay Rheumatology Medical Group, Inc.</name>
      <address>
        <city>San Leandro</city>
        <state>California</state>
        <zip>94578</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Arthritis Ctr Med Group</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inland Rheumatology Clinical Trials, Inc.</name>
      <address>
        <city>Upland</city>
        <state>California</state>
        <zip>91786</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Denver Arthritis Clinic</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Javed Rheumatology Associates</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>19713</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>RASF - Clinical Research Center</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suncoast Research Group LLC</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33135</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Medical center &amp; Research Inc</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33142</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Omega Research Consultants</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32810</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Family Clinical Trials, LLC.</name>
      <address>
        <city>Pembroke Pines</city>
        <state>Florida</state>
        <zip>33026</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McIlwain Medical Group, PA</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33613</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AdventHealth Medical Group, PA</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33614</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Center of North Georgia</name>
      <address>
        <city>Gainesville</city>
        <state>Georgia</state>
        <zip>30501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institute of Arthritis Research</name>
      <address>
        <city>Idaho Falls</city>
        <state>Idaho</state>
        <zip>83404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Clinical Research</name>
      <address>
        <city>Meridian</city>
        <state>Idaho</state>
        <zip>83642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Graves Gilbert Clinic</name>
      <address>
        <city>Bowling Green</city>
        <state>Kentucky</state>
        <zip>42101</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Arthritis &amp; Diabetes Clinic, Inc.</name>
      <address>
        <city>Monroe</city>
        <state>Louisiana</state>
        <zip>71203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates, M.D., P.A.</name>
      <address>
        <city>Cumberland</city>
        <state>Maryland</state>
        <zip>21502</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klein and Associates, M.D., P.A.</name>
      <address>
        <city>Hagerstown</city>
        <state>Maryland</state>
        <zip>21740</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Rheumatology and Bone Research</name>
      <address>
        <city>Wheaton</city>
        <state>Maryland</state>
        <zip>20902</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Pharmacology Study Group</name>
      <address>
        <city>Worcester</city>
        <state>Massachusetts</state>
        <zip>01605</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Glacier View Research Instutute-Rheumatology</name>
      <address>
        <city>Kalispell</city>
        <state>Montana</state>
        <zip>59901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis &amp; Osteoporosis Associates, PA</name>
      <address>
        <city>Freehold</city>
        <state>New Jersey</state>
        <zip>07728</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lovelace Scientific Resources, Inc.</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87108</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Ambulatory Care</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>110201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medication Management, LLC</name>
      <address>
        <city>Greensboro</city>
        <state>North Carolina</state>
        <zip>27408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cape Fear Arthritis Care</name>
      <address>
        <city>Leland</city>
        <state>North Carolina</state>
        <zip>28451</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carolina Arthritis Associates</name>
      <address>
        <city>Wilmington</city>
        <state>North Carolina</state>
        <zip>28401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Trinity Medical Group</name>
      <address>
        <city>Minot</city>
        <state>North Dakota</state>
        <zip>58701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cincinnati Rheumatic Disease Study Group</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>STAT Research, Inc.</name>
      <address>
        <city>Dayton</city>
        <state>Ohio</state>
        <zip>45417</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Source, Inc.</name>
      <address>
        <city>Perrysburg</city>
        <state>Ohio</state>
        <zip>43606</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arthritis Group</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19152</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Low Country Research Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center Inflammatory Disease</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Amarillo Center for Clinical Research</name>
      <address>
        <city>Amarillo</city>
        <state>Texas</state>
        <zip>79124</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Regional Clinic, P.A.</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research, Inc.</name>
      <address>
        <city>Baytown</city>
        <state>Texas</state>
        <zip>77521</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Group of SE Texas</name>
      <address>
        <city>Beaumont</city>
        <state>Texas</state>
        <zip>77701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Precision Comprehensive Clinical Research Solutions</name>
      <address>
        <city>Grapevine</city>
        <state>Texas</state>
        <zip>76034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Therapeutic Concepts Rheumatology, LLC</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77034</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumatology Clinic of Houston, P.A.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pioneer Research Solutions, Inc.</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77429</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Endocrinology, Internal Medicine</name>
      <address>
        <city>Lubbock</city>
        <state>Texas</state>
        <zip>79410</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accurate Clinical Research, Inc.</name>
      <address>
        <city>Nassau Bay</city>
        <state>Texas</state>
        <zip>77058</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dr. Alex De Jesus Rheumatology, P.A.</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Advanced Rheumatology of Houston</name>
      <address>
        <city>Woodville</city>
        <state>Texas</state>
        <zip>77382</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>West Virginia Research Institute</name>
      <address>
        <city>South Charleston</city>
        <state>West Virginia</state>
        <zip>25309</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Italiano Regional del Sur</name>
      <address>
        <city>Bahia Blanca</city>
        <state>Buenos Aires</state>
        <zip>B8001HXM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Medicas Mar del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FYK</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas-Mar del Plata</name>
      <address>
        <city>Mar del Plata</city>
        <state>Buenos Aires</state>
        <zip>B7600FZ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Investigaciones Clinicas Quilmes</name>
      <address>
        <city>Quilmes</city>
        <state>Buenos Aires</state>
        <zip>B1878DVB</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio Delta</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000BIF</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Higado y Aparato Digestivo</name>
      <address>
        <city>Rosario</city>
        <state>Santa Fe</state>
        <zip>S2000</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sanatorio San Martin</name>
      <address>
        <city>Venado Tuerto</city>
        <state>Santa Fe</state>
        <zip>S2600KUE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Medico Privado de Reumatologia</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000AXL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Reumatológicas</name>
      <address>
        <city>San Miguel de Tucuman</city>
        <state>Tucuman</state>
        <zip>T4000BRD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto de Asistencia</name>
      <address>
        <city>Buenos Aires</city>
        <zip>B1646DBM</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Organizacion Medica de Investigacion (OMI)</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1015ABO</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>APRILLUS</name>
      <address>
        <city>Ciudad Autonoma Buenos aires</city>
        <zip>C1046AAQ</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Centenario</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1204AAD</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General de Agudos Dr. J. M. Ramos Mejia</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1221ADC</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Atencion Integral en Reumatologia (AIR)</name>
      <address>
        <city>Ciudad Autonoma Buenos Aires</city>
        <zip>C1426AAL</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto DAMIC Fundacion Rusculleda</name>
      <address>
        <city>Cordoba</city>
        <zip>X5003DCE</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Privado Centro Medico de Cordoba</name>
      <address>
        <city>Cordoba</city>
        <zip>X5016KEH</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro Polivalente de Asistencia e Inv. Clinica CER</name>
      <address>
        <city>San Juan</city>
        <zip>5400</zip>
        <country>Argentina</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará</name>
      <address>
        <city>Fortaleza</city>
        <state>Ceará</state>
        <zip>60430-370</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CEDOES - Diagnóstico e Pesquisa</name>
      <address>
        <city>Vitória</city>
        <state>Espírito Santo</state>
        <zip>29055-450</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIP - Centro Internacional de Pesquisa</name>
      <address>
        <city>Goiânia</city>
        <state>Goiás</state>
        <zip>74110-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CMiP - Centro Mineiro de Pesquisa</name>
      <address>
        <city>Juiz de Fora</city>
        <state>Minas Gerais</state>
        <zip>36010-570</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CETI - Centro de Estudos em Terapias Inovadoras Ltda.</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>80030-110</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinilive - Clínica do Idoso e Pesquisa Clínica</name>
      <address>
        <city>Maringá</city>
        <state>Paraná</state>
        <zip>87015-180</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bruno Born</name>
      <address>
        <city>Lajeado</city>
        <state>Rio Grande Do Sul</state>
        <zip>95900-010</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMK Serviços Médicos S/S Ltda</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande Do Sul</state>
        <zip>90480-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Faculdade de Medicina do ABC</name>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>09060-870</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Estadual Mário Covas</name>
      <address>
        <city>Santo André</city>
        <state>Sao Paulo</state>
        <zip>9190510</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HUCFF-UFRJ - Hospital Universitário Clementino Fraga Filho - Universidade Federal do Rio de Janeiro</name>
      <address>
        <city>Rio de Janeiro</city>
        <zip>21941-913</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital São Vicente de Paulo</name>
      <address>
        <city>Rio Grande</city>
        <zip>99010-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clínica de Neoplasias Litoral Ltda.</name>
      <address>
        <city>Santa Catarina</city>
        <zip>88301-220</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Abreu Sodré - AACD</name>
      <address>
        <city>Sao Paulo</city>
        <zip>04023-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CPCLIN - Centro de Pesquisas Clínicas Ltda.</name>
      <address>
        <city>São Paulo</city>
        <zip>01228-200</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Reumatologia y Ortopedia SAS</name>
      <address>
        <city>Barranquilla</city>
        <zip>080020</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Hospital Universidad del Norte</name>
      <address>
        <city>Barranquilla</city>
        <zip>111211</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacion Instituto de Reumatologia Fernando Chalem</name>
      <address>
        <city>Bogota</city>
        <zip>00000</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion en Reumatologia y Especialidades Medicas SAS. CIREEM</name>
      <address>
        <city>Bogotá</city>
        <zip>110221</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medicity S.A.S.</name>
      <address>
        <city>Bucaramanga</city>
        <zip>680003</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Artritis Temprana S.A.</name>
      <address>
        <city>Cali</city>
        <zip>76001</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Pablo Tobón Uribe</name>
      <address>
        <city>Medellín</city>
        <zip>050034</zip>
        <country>Colombia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Brno S.R.O.</name>
      <address>
        <city>Brno</city>
        <zip>602 00</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Revmatologie MUDr. Klara Sirova s.r.o.</name>
      <address>
        <city>Ostrava - Moravska Ostrava</city>
        <zip>70200</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CCR Pardubice</name>
      <address>
        <city>Pardubice</city>
        <zip>53002</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MEDICAL PLUS s.r.o.</name>
      <address>
        <city>Uherske Hradiste</city>
        <zip>68601</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>PV - Medical, s.r.o.</name>
      <address>
        <city>Zlin</city>
        <zip>760 01</zip>
        <country>Czechia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kerckhoff-Klinik gGmbH</name>
      <address>
        <city>Bad Nauheim</city>
        <state>Hessen</state>
        <zip>61231</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CIRI - Centrum für Innovative Diagnostik und Therapie GmbH</name>
      <address>
        <city>Frankfurt</city>
        <state>Hessen</state>
        <zip>60590</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMO.MD GmbH</name>
      <address>
        <city>Magdeburg</city>
        <state>Sachsen Anhalt</state>
        <zip>39120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>KH Dresden-Friedrichstadt</name>
      <address>
        <city>Dresden</city>
        <state>Sachsen</state>
        <zip>01067</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rheumapraxis Dr. med. Reiner Kurthen</name>
      <address>
        <city>Aachen</city>
        <zip>52064</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charite Universitaetsmedizin Berlin - Campus Charite Mitte</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klin.Forsch. Berlin-Mitt GmbH</name>
      <address>
        <city>Berlin</city>
        <zip>13125</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>HRF Hamburger Rheuma Forschungszentrum</name>
      <address>
        <city>Hamburg</city>
        <zip>20095</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schoen Klinik Hamburg Eilbek</name>
      <address>
        <city>Hamburg</city>
        <zip>22081</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinexpert Egeszsegugyi Szolg. es Ker. Kft.</name>
      <address>
        <city>Budapest</city>
        <zip>1033</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Obudai Egeszsegugyi Centrum</name>
      <address>
        <city>Budapest</city>
        <zip>1036</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MAV Korhaz és Rendelointezet</name>
      <address>
        <city>Szolnok</city>
        <zip>5000</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vital Medical Center</name>
      <address>
        <city>Veszprem</city>
        <zip>8200</zip>
        <country>Hungary</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ajou University Hospital</name>
      <address>
        <city>Suwon-si</city>
        <state>Gyeonggi-do</state>
        <zip>16499</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonbuk National University Hospital</name>
      <address>
        <city>Chungbuk</city>
        <zip>54907</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35015</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eulji University Hospital</name>
      <address>
        <city>Daejeon</city>
        <zip>35233</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <zip>61469</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHA Bundang Medical Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13496</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>431-796</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Jeju National University Hospital</name>
      <address>
        <city>Jeju</city>
        <zip>63241</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University</name>
      <address>
        <city>Seoul</city>
        <zip>3722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Clínica GRAMEL S.C</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>03720</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinstile, S.A. de C.V.</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>06700</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Comop, A.C.</name>
      <address>
        <city>Mexico</city>
        <state>Distrito Federal</state>
        <zip>16100</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Institute S.C.</name>
      <address>
        <city>Tlalnepantla</city>
        <state>Estado De Mexico</state>
        <zip>54055</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinica de Investigacion en Reumatologia y Obesidad S.C.</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44650</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Estudios de Investigacion Basica y Clinica SC</name>
      <address>
        <city>Guadalajara</city>
        <state>Jalisco</state>
        <zip>44690</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Accelerium S. de R.L. de C.V.</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital y Clinica OCA SA de CV</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universidad Autonoma de Nuevo Leon, Hospital Universitario Dr. Jose Eleuterio Gonzalez</name>
      <address>
        <city>Monterrey</city>
        <state>Nuevo León</state>
        <zip>64460</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Alta Especialidad en Reumatología e Investigación del Potosí, S.C.</name>
      <address>
        <city>San Luis Potosi</city>
        <state>San Luis Potos</state>
        <zip>78213</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigacion y Biomedicina de Chihuahua, S.C.</name>
      <address>
        <city>Chihuahua</city>
        <zip>31000</zip>
        <country>Mexico</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Uniwersytecki nr 2 im.dr J. Biziela</name>
      <address>
        <city>Bydgoszcz</city>
        <zip>85-168</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Specjalistyczny nr 1 w</name>
      <address>
        <city>Bytom</city>
        <zip>41902</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McBk S.C.</name>
      <address>
        <city>Grodzisk Mazowiecki</city>
        <zip>05-825</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Polimedica Centrum Badań, Profilaktyki I Leczenia</name>
      <address>
        <city>Kielce</city>
        <zip>25-355</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centrum Medyczne AMED</name>
      <address>
        <city>Lodz</city>
        <zip>91-363</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Szpital Wojewodzki im. Prymasa Kardynala Stefana Wyszynskiego</name>
      <address>
        <city>Sieradz</city>
        <zip>98-200</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samodzielny Publiczny ZOZ Tomaszow Lubelski</name>
      <address>
        <city>Tomaszow Lubelski</city>
        <zip>22-600</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>McM Polimedica</name>
      <address>
        <city>Warszawa</city>
        <zip>02-777</zip>
        <country>Poland</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Center n a Almazov</name>
      <address>
        <city>Saint-Petersburg</city>
        <state>Leningrad Oblast</state>
        <zip>197341</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution of Moscow &quot;City Clinical Hospital #1 n.a. Pirogov&quot; Healthcare Departament of Moscow</name>
      <address>
        <city>Moscow</city>
        <state>Moscovskaya Oblast</state>
        <zip>119049</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University hospital #3</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Oblast</state>
        <zip>119991</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital #1</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Oblast</state>
        <zip>119992</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University n a Evdokimov</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Oblast</state>
        <zip>121374</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Budgetary Healthcare Institution &quot;City Clinical Hospital # 15 n.a O.M. Filatov&quot; of Moscow Healtheare Department</name>
      <address>
        <city>Moscow</city>
        <state>Moscow Region</state>
        <zip>111539</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>City Clinical Hospital #1</name>
      <address>
        <city>Novosibirsk</city>
        <state>Novosibirsk Oblast</state>
        <zip>630099</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Diagnostic Center Ultramed</name>
      <address>
        <city>Omsk</city>
        <state>Omsk Oblast</state>
        <zip>644024</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of the Republic of Karelia &quot;Republican Hospital named after V.A.Baranov&quot;</name>
      <address>
        <city>Petrozavodsk</city>
        <state>Republic Of Karelia</state>
        <zip>185019</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rostov State Medical Unversity</name>
      <address>
        <city>Rostov-on-Don</city>
        <state>Rostov Oblast</state>
        <zip>344022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Saratov</city>
        <state>Saratov Oblast</state>
        <zip>410053</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hosp n a Mirotvorcev</name>
      <address>
        <city>Saratov</city>
        <state>Saratov Oblast</state>
        <zip>410054</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SBHI of Stavropol Region &quot;Stavropol Regional Clinical Hospital&quot;</name>
      <address>
        <city>Stavropol'</city>
        <state>Stavropol Region</state>
        <zip>355000</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>State Autonomous Healthcare Institution &quot;Republican Clinical Hospital of Ministry of Health of Tatarstan Republic</name>
      <address>
        <city>Kazan'</city>
        <state>The Republic Of Tatarstan</state>
        <zip>420064</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siberian Medical University</name>
      <address>
        <city>Tomsk</city>
        <state>Tomsk Oblast</state>
        <zip>634050</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Regional Clinical Hospital</name>
      <address>
        <city>Vladimir</city>
        <state>Vladimir Oblast</state>
        <zip>600023</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University n a Burdenko</name>
      <address>
        <city>Voronezh</city>
        <state>Voronezh Oblast</state>
        <zip>394066</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Hospital 3</name>
      <address>
        <city>Yaroslavl</city>
        <state>Yaroslavl Oblast</state>
        <zip>150051</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>FSBSI &quot;Scientific Research Institute of Rheumatology n.a. V.A. Nasonova&quot;</name>
      <address>
        <city>Moscow</city>
        <zip>115478</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Brazil</country>
    <country>Colombia</country>
    <country>Czechia</country>
    <country>Germany</country>
    <country>Hungary</country>
    <country>Korea, Republic of</country>
    <country>Mexico</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Czech Republic</country>
    <country>Turkey</country>
  </removed_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>April 29, 2016</study_first_submitted>
  <study_first_submitted_qc>May 2, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <results_first_submitted>January 26, 2021</results_first_submitted>
  <results_first_submitted_qc>June 30, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 21, 2021</results_first_posted>
  <last_update_submitted>June 30, 2021</last_update_submitted>
  <last_update_submitted_qc>June 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>moderate Rheumatoid Arthritis</keyword>
  <keyword>severe Rheumatoid Arthritis</keyword>
  <keyword>Olokizumab</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Necrosis</mesh_term>
  </condition_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 28, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/33/NCT02760433/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Enrollment was conducted at 123 clinical sites across 11 countries (US,EU, Russian Federation, Asia, Latin America). 718 subjects were screened and 368 subjects were enrolled (randomized) and treated, 318 subjects completed the study. A total of 368 subjects were analyzed for efficacy in the ITT Population and 368 subjects were analyzed for safety in the Safety Population.</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Arm 1: Olokizumab q4w</title>
          <description>Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate&#xD;
Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)&#xD;
There was no re-randomization at week 16 for this arm</description>
        </group>
        <group group_id="P2">
          <title>Arm 2: Olokizumab q2w</title>
          <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)&#xD;
There was no re-randomization at week 16 for this arm</description>
        </group>
        <group group_id="P3">
          <title>Arm 4: Placebo-OKZ 64 mg q4w</title>
          <description>refers to subjects who initially received placebo q2w (Arm 3:Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate)), but then were re-randomized at week 16 to receive OKZ 64 mg q4w. Arm 3 (placebo q2w) consisted of subjects from arms 4, 5 and 6.</description>
        </group>
        <group group_id="P4">
          <title>Arm 5: Placebo-OKZ 64 mg q2w</title>
          <description>refers to subjects who initially received placebo q2w (Arm 3:Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate)), but then were re-randomized at week 16 to receive OKZ 64 mg q2w. Arm 3 (placebo q2w) consisted of subjects from arms 4, 5 and 6.</description>
        </group>
        <group group_id="P5">
          <title>Arm 6:Placebo Only</title>
          <description>refers to subjects who were initially randomized to placebo q2w (Arm3:Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate)), but who were not re-randomized to OKZ 64 mg q2w or OKZ 64 mg q4w. Arm 3 (placebo q2w) consisted of subjects from arms 4, 5 and 6.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="161"/>
                <participants group_id="P2" count="138"/>
                <participants group_id="P3" count="26"/>
                <participants group_id="P4" count="32"/>
                <participants group_id="P5" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="134"/>
                <participants group_id="P2" count="128"/>
                <participants group_id="P3" count="25"/>
                <participants group_id="P4" count="30"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
                <participants group_id="P2" count="10"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="10"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="23"/>
                <participants group_id="P2" count="9"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="2"/>
                <participants group_id="P5" count="9"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lack of Response At Week 14</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject refused to continue the study</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Subject was taking prohibited medications and refused to stop.</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Ongoing Adverse Events (low platelet count) with long interruptions of investigational product</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Arms 4, 5 and 6 include all subjects from the arm 3. Patients at Arm 3 (placebo q2w) received placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w;</population>
      <group_list>
        <group group_id="B1">
          <title>Arm 1: Olokizumab q4w</title>
          <description>Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate&#xD;
Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)</description>
        </group>
        <group group_id="B2">
          <title>Arm 2: Olokizumab q2w</title>
          <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
        </group>
        <group group_id="B3">
          <title>Arm 4: Placebo-OKZ 64 mg q4w</title>
          <description>refers to subjects who initially received placebo q2w, but then were re-randomized at week 16 to receive OKZ 64 mg q4w</description>
        </group>
        <group group_id="B4">
          <title>Arm 5: Placebo-OKZ 64 mg q2w</title>
          <description>refers to subjects who initially received placebo q2w, but then were re-randomized at week 16 to receive OKZ 64 mg q2w</description>
        </group>
        <group group_id="B5">
          <title>Arm 6:Placebo Only</title>
          <description>refers to subjects who were initially randomized to placebo, but who were not re-randomized to OKZ 64 mg q2w or OKZ 64 mg q4w</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="161"/>
            <count group_id="B2" value="138"/>
            <count group_id="B3" value="26"/>
            <count group_id="B4" value="32"/>
            <count group_id="B5" value="11"/>
            <count group_id="B6" value="368"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="132"/>
                    <measurement group_id="B2" value="114"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="7"/>
                    <measurement group_id="B6" value="300"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="29"/>
                    <measurement group_id="B2" value="24"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="4"/>
                    <measurement group_id="B6" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.9" spread="11.68"/>
                    <measurement group_id="B2" value="53.4" spread="12.68"/>
                    <measurement group_id="B3" value="53.5" spread="14.13"/>
                    <measurement group_id="B4" value="53.9" spread="11.67"/>
                    <measurement group_id="B5" value="48.9" spread="18.28"/>
                    <measurement group_id="B6" value="53.5" spread="12.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="130"/>
                    <measurement group_id="B2" value="122"/>
                    <measurement group_id="B3" value="20"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="8"/>
                    <measurement group_id="B6" value="307"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="31"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="5"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Black of African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="139"/>
                    <measurement group_id="B2" value="110"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="302"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other/Mixed</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="6"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Colombia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Argentina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>South Korea</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hungary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="63"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Czechia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Brazil</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Poland</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="2"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mexico</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="8"/>
                    <measurement group_id="B5" value="2"/>
                    <measurement group_id="B6" value="73"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Germany</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Russia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Body Mass Index (BMI),Continuous</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="29.218" lower_limit="17.99" upper_limit="56.25"/>
                    <measurement group_id="B2" value="28.755" lower_limit="17.78" upper_limit="57.93"/>
                    <measurement group_id="B3" value="28.895" lower_limit="20.74" upper_limit="49.93"/>
                    <measurement group_id="B4" value="28.467" lower_limit="17.82" upper_limit="37.60"/>
                    <measurement group_id="B5" value="26.976" lower_limit="21.09" upper_limit="38.37"/>
                    <measurement group_id="B6" value="28.888" lower_limit="17.78" upper_limit="57.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>ACR20 Response</title>
        <description>The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.&#xD;
American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab 64 mg q4w</title>
            <description>Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate&#xD;
Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab 64 mg q2w</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w</title>
            <description>Placebo q2w subcutaneous + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)&#xD;
Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w;&#xD;
Arm 3 (placebo q2w) consisted of subjects from arms 4, 5 and 6 reported previously</description>
          </group>
        </group_list>
        <measure>
          <title>ACR20 Response</title>
          <description>The difference between OKZ and placebo in the percentage of subjects achieving an ACR20 response and remaining on randomized treatment and in the study at Week 12. A responder is defined as any subject satisfying ACR20 criteria and remaining on randomized treatment and in the study at Week 12.&#xD;
American College of Rheumatology 20 % response is a composite defined as a ≥ 20% improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥20% improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="96"/>
                    <measurement group_id="O2" value="84"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ACR20 response rate at Week 12 for the placebo group is estimated to be 20% in this study population. The OKZ ACR20 response rate for 64 mg q4w treatment group at Week 12 are expected to be at least 45%, resulting in an expected difference in ACR20 response rates of 25 percentage points between the respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0125</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.190</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.030</ci_lower_limit>
            <ci_upper_limit>0.337</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The ACR20 response rate at Week 12 for the placebo group is estimated to be 20% in this study population .The OKZ ACR20 response rate for 64 mg q2w treatment group at Week 12 is expected to be at least 50%, resulting in an expected difference in ACR20 response rates of 30 percentage points between the respective OKZ treatment group and placebo. Sample size yield 100% disjunctive power for testing the primary hypothesis</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0125</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.203</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.038</ci_lower_limit>
            <ci_upper_limit>0.353</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between OKZ and Placebo in the Percentage of Subjects Achieving Low Disease Activity</title>
        <description>Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w</title>
            <description>Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate&#xD;
Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w</title>
            <description>Placebo q2w subcutaneous + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)&#xD;
Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w;&#xD;
Arm 3 (placebo q2w) consisted of subjects from arms 4, 5 and 6 reported previously</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between OKZ and Placebo in the Percentage of Subjects Achieving Low Disease Activity</title>
          <description>Defined as Disease Activity Score 28-joint count (DAS28) C-reactive protein (CRP) &lt;3.2, and remaining on randomized treatment and in the study at Week 12</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="55"/>
                    <measurement group_id="O3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The DAS28 low disease activity (based on DAS28 [CRP] &lt;3.2) response rate at Week 12 was estimated to be 5% in the placebo group and 18% and 21% in 64 mg q4w and q2w OKZ groups, respectively, resulting in an expected difference of 13 and 16 percentage points between respective OKZ groups and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0125</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.164</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.029</ci_lower_limit>
            <ci_upper_limit>0.268</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>The DAS28 low disease activity (based on DAS28 [CRP] &lt;3.2) response rate at Week 12 was estimated to be 5% in the placebo group and 18% and 21% in 64 mg q4w and q2w OKZ groups, respectively, resulting in an expected difference of 13 and 16 percentage points between respective OKZ groups and placebo.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>&lt;0.0125</p_value>
            <method>Chi-squared</method>
            <method_desc>2x2 chi-square test</method_desc>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.283</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.139</ci_lower_limit>
            <ci_upper_limit>0.396</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Difference Between OKZ and Placebo in the Improvement of Physical Ability</title>
        <description>Improvement of physical ability from baseline to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 to 3, with higher scores indicating greater disability.</description>
        <time_frame>Baseline to Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w</title>
            <description>Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate&#xD;
Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w + Methotrexate</title>
            <description>Placebo q2w subcutaneous + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)&#xD;
Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w;&#xD;
Arm 3 (placebo q2w) consisted of subjects from arms 4, 5 and 6 reported previously</description>
          </group>
        </group_list>
        <measure>
          <title>Difference Between OKZ and Placebo in the Improvement of Physical Ability</title>
          <description>Improvement of physical ability from baseline to week 12, as measured by HAQ-DI. The HAQ-DI assesses the degree of difficulty experienced in 8 domains of daily living activities using 20 questions. The domains are dressing and grooming, arising, eating, walking, hygiene, reach, grip and common daily activities, and each domain consists of 2 or 3 items. For each question, the level of difficulty is scored from 0 to 3 where 0 = without any difficulty (the best outcome), 1 = with some difficulty, 2 = much difficulty, and 3 = unable to do (the worst outcome). Each category is given a score by taking the maximum score of each question. A decrease from baseline indicates improvement for HAQ-DI. The HAQ-DI was calculated by dividing the sum of the category scores by the number of categories with at least 1 question answered. The HAQ-DI total score ranges from 0 to 3, with higher scores indicating greater disability.</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis</population>
          <units>score on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.78" spread="0.558"/>
                    <measurement group_id="O2" value="1.79" spread="0.533"/>
                    <measurement group_id="O3" value="1.78" spread="0.639"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Week 12 (visit 9)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.37" spread="0.613"/>
                    <measurement group_id="O2" value="1.30" spread="0.626"/>
                    <measurement group_id="O3" value="1.49" spread="0.642"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Change from Baseline (Observed and Imputed)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.39" spread="0.048"/>
                    <measurement group_id="O2" value="-0.49" spread="0.056"/>
                    <measurement group_id="O3" value="-0.32" spread="0.063"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.1814</p_value>
            <p_value_desc>p-value was greater than the threshold p-value of 0.0125</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.07</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.081</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.26</ci_lower_limit>
            <ci_upper_limit>0.11</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>=0.0227</p_value>
            <p_value_desc>p-value was greater than the threshold p-value of 0.0125</p_value_desc>
            <method>ANCOVA</method>
            <param_type>Least Squares Mean Difference</param_type>
            <param_value>-0.17</param_value>
            <dispersion_type>Standard Error of the Mean</dispersion_type>
            <dispersion_value>0.083</dispersion_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.02</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>ACR50 Response</title>
        <description>Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 12.&#xD;
American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w</title>
            <description>Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate&#xD;
Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w</title>
            <description>Placebo q2w subcutaneous + Methotrexate&#xD;
Placebo q2w subcutaneous + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)&#xD;
Arm 3 (placebo q2w) consisted of subjects from arms 4, 5 and 6 reported previously Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w;</description>
          </group>
        </group_list>
        <measure>
          <title>ACR50 Response</title>
          <description>Difference between OKZ and placebo in the percentage of subjects achieving an ACR50 response and remaining on randomized treatment and in the study at Week 12.&#xD;
American College of Rheumatology 50% Response is a composite defined as ≥50%, improvement from baseline in the swollen joint counts assessed in 66 joints and in the tender joint count assessed in 68 joints; and a ≥50%, improvement from baseline in at least 3 of the 5 remaining core set measures:&#xD;
Patient Global Assessment of Disease Activity (VAS)&#xD;
Patient Assessment of Pain (VAS)&#xD;
HAQ-DI&#xD;
Physician Global Assessment (VAS)&#xD;
Level of acute phase reactant (CRP)</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52"/>
                    <measurement group_id="O2" value="46"/>
                    <measurement group_id="O3" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.164</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.020</ci_lower_limit>
            <ci_upper_limit>0.278</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.174</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.027</ci_lower_limit>
            <ci_upper_limit>0.294</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Clinical Disease Activity Index (CDAI) ≤2.8 (Remission)</title>
        <description>Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 12</description>
        <time_frame>at Week 12</time_frame>
        <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
        <group_list>
          <group group_id="O1">
            <title>Arm 1: Olokizumab q4w</title>
            <description>Olokizumab 64mg subcutaneous q4w +placebo + Methotrexate&#xD;
Olokizumab 64 mg subcutaneous q4w + placebo+ concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular) in order to maintain the blind, subjects randomized to receive OKZ q4w received placebo injections at the alternate q4w interval (e.g., Week 2, Week 6, etc.)</description>
          </group>
          <group group_id="O2">
            <title>Arm 2: Olokizumab q2w</title>
            <description>Olokizumab 64mg subcutaneous q2w + Methotrexate&#xD;
64 mg Olokizumab administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)</description>
          </group>
          <group group_id="O3">
            <title>Arm 3: Placebo q2w</title>
            <description>Placebo q2w subcutaneous + Methotrexate&#xD;
Placebo administered subcutaneously once every 2 weeks + concomitant background therapy (Methotrexate) at a stable dose with a stable route of administration (oral, subcutaneous, or intramuscular)&#xD;
Starting at Week 16, all subjects in the placebo group were randomized in a blinded fashion to receive either OKZ 64 mg q2w or OKZ 64 mg q4w;&#xD;
Arm 3 (placebo q2w) consisted of subjects from arms 4, 5 and 6 reported previously</description>
          </group>
        </group_list>
        <measure>
          <title>Clinical Disease Activity Index (CDAI) ≤2.8 (Remission)</title>
          <description>Difference between OKZ and placebo in the percentage of subjects with Clinical Disease Activity Index (CDAI) ≤2.8 (remission) and remaining on randomized treatment and in the study at Week 12</description>
          <population>Intent-to-treat (ITT) population: The ITT population includes all randomized subjects. Subjects were analyzed according to the treatment group to which they were randomized. The ITT population is the primary analysis population.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="161"/>
                <count group_id="O2" value="138"/>
                <count group_id="O3" value="69"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                    <measurement group_id="O2" value="9"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.031</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.052</ci_lower_limit>
            <ci_upper_limit>0.083</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <param_type>Risk Difference (RD)</param_type>
            <param_value>0.065</param_value>
            <ci_percent>97.5</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.023</ci_lower_limit>
            <ci_upper_limit>0.134</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>All AEs were collected from the signature of the informed consent form until the last visit of the subject in the study (up to 22 weeks after the final dose of study treatment) regardless of relationship to study treatment, up to approximately 44 weeks. Any SAE with a start date after the Safety Follow-Up Period was not required to be reported unless the Investigator thought that the event might be related to either the study treatment, study treatment administration, or a protocol procedure</time_frame>
      <desc>All AEs and SAEs reported below are related to the Safety Population (safety population included all subjects who receive at least 1 dose of study treatment).&#xD;
Data for TEAEs were reported below. A Treatment Emergent Adverse Event (TEAE) is defined as an AE that first occurred or worsened in severity after the first dose of the study treatment.</desc>
      <group_list>
        <group group_id="E1">
          <title>Arm 1: OKZ 64 mg q4w</title>
          <description>refers to subjects initially randomized to receive OKZ q4w and relates to AEs reported for this group during the total 24-week study treatment period</description>
        </group>
        <group group_id="E2">
          <title>Arm 2: OKZ 64 mg q2w</title>
          <description>refers to subjects initially randomized to receive OKZ q2w and relates to AEs reported for this group during the total 24-week study treatment period</description>
        </group>
        <group group_id="E3">
          <title>Arm 3: Placebo q2w</title>
          <description>refers to subjects initially randomized to receive placebo and relates only to AEs reported for this group during the 16-week treatment period up to re-randomization</description>
        </group>
        <group group_id="E4">
          <title>Arm 4: Placebo-OKZ 64 mg q4w</title>
          <description>refers to subjects re-randomized to receive OKZ q4w and relates only to AEs reported for this group during the treatment period after re-randomization from Week 16 to Week 24</description>
        </group>
        <group group_id="E5">
          <title>Arm 5: Placebo-OKZ 64 mg q2w</title>
          <description>refers to subjects re-randomized to receive OKZ q2w and relates only to AEs reported for this group during the treatment period after re-randomization from Week 16 to Week 24</description>
        </group>
        <group group_id="E6">
          <title>Arm 6: Any OKZ 64 mg q4w</title>
          <description>refers to a combination of the AEs reported for the OKZ 64 mg q4w group and the Placebo-OKZ 64 mg q4w group</description>
        </group>
        <group group_id="E7">
          <title>Arm 7: Any OKZ 64 mg q2w</title>
          <description>refers to a combination of the AEs reported for the OKZ 64 mg q2w group and the Placebo-OKZ 64 mg q2w group</description>
        </group>
        <group group_id="E8">
          <title>Arm 8:Total</title>
          <description>refers to AEs reported for all subjects at all visits</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E8" subjects_affected="0" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E7" subjects_affected="12" subjects_at_risk="171"/>
                <counts group_id="E8" subjects_affected="18" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Sinus bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gastrointestinal disorder</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Cholecystitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaphylactic reaction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="2" subjects_affected="2" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Pilonidal cyst</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hip fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Ulna fracture</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Transaminases increased</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Intervertebral disc protrusion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Musculoskeletal chest pain</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Osteoarthritis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Invasive ductal breast carcinoma</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E7" events="0" subjects_affected="0" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertensive crisis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="1" subjects_affected="1" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>4</frequency_threshold>
        <default_vocab>MedDRA 22.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="160"/>
                <counts group_id="E2" subjects_affected="38" subjects_at_risk="139"/>
                <counts group_id="E3" subjects_affected="16" subjects_at_risk="69"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="26"/>
                <counts group_id="E5" subjects_affected="8" subjects_at_risk="32"/>
                <counts group_id="E6" subjects_affected="40" subjects_at_risk="186"/>
                <counts group_id="E7" subjects_affected="46" subjects_at_risk="171"/>
                <counts group_id="E8" subjects_affected="98" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" events="1" subjects_affected="1" subjects_at_risk="186"/>
                <counts group_id="E7" events="3" subjects_affected="3" subjects_at_risk="171"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="160"/>
                <counts group_id="E2" events="6" subjects_affected="6" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" events="3" subjects_affected="3" subjects_at_risk="186"/>
                <counts group_id="E7" events="8" subjects_affected="8" subjects_at_risk="171"/>
                <counts group_id="E8" events="11" subjects_affected="11" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Injection site erythema</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E7" events="1" subjects_affected="1" subjects_at_risk="171"/>
                <counts group_id="E8" events="8" subjects_affected="8" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="7" subjects_affected="7" subjects_at_risk="160"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E8" events="18" subjects_affected="18" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="6" subjects_affected="6" subjects_at_risk="186"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E8" events="16" subjects_affected="16" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Latent tuberculosis</sub_title>
                <counts group_id="E1" events="6" subjects_affected="6" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="2" subjects_affected="2" subjects_at_risk="32"/>
                <counts group_id="E6" events="7" subjects_affected="7" subjects_at_risk="186"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E8" events="13" subjects_affected="13" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="160"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="139"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="0" subjects_affected="0" subjects_at_risk="186"/>
                <counts group_id="E7" events="6" subjects_affected="6" subjects_at_risk="171"/>
                <counts group_id="E8" events="10" subjects_affected="10" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" events="13" subjects_affected="13" subjects_at_risk="160"/>
                <counts group_id="E2" events="10" subjects_affected="10" subjects_at_risk="139"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="13" subjects_affected="13" subjects_at_risk="186"/>
                <counts group_id="E7" events="11" subjects_affected="11" subjects_at_risk="171"/>
                <counts group_id="E8" events="24" subjects_affected="24" subjects_at_risk="368"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" events="8" subjects_affected="8" subjects_at_risk="160"/>
                <counts group_id="E2" events="9" subjects_affected="9" subjects_at_risk="139"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="69"/>
                <counts group_id="E4" events="0" subjects_affected="0" subjects_at_risk="26"/>
                <counts group_id="E5" events="1" subjects_affected="1" subjects_at_risk="32"/>
                <counts group_id="E6" events="8" subjects_affected="8" subjects_at_risk="186"/>
                <counts group_id="E7" events="10" subjects_affected="10" subjects_at_risk="171"/>
                <counts group_id="E8" events="19" subjects_affected="19" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="160"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="139"/>
                <counts group_id="E3" events="3" subjects_affected="3" subjects_at_risk="69"/>
                <counts group_id="E4" events="1" subjects_affected="1" subjects_at_risk="26"/>
                <counts group_id="E5" events="0" subjects_affected="0" subjects_at_risk="32"/>
                <counts group_id="E6" events="2" subjects_affected="2" subjects_at_risk="186"/>
                <counts group_id="E7" events="4" subjects_affected="4" subjects_at_risk="171"/>
                <counts group_id="E8" events="9" subjects_affected="9" subjects_at_risk="368"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Any study related information could be made public available only after Sponsors written permission.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Elena Korneva, Senior Scientific Advisor</name_or_title>
      <organization>R-Pharm</organization>
      <phone>0074959567937 ext 3819</phone>
      <email>korneva@rpharm.ru</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

